Irisin as a marker of hepatic steatosis in children with metabolic dysfunction–associated steatotic liver disease
Acta Paediatrica · 2025-03 · 114 (3) · 578-585
DOI: 10.1111/apa.17475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Paediatrica, online erschienen am 24.10.2024. Verfasst von Katarzyna Zdanowicz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Gastroenterology, Hepatology, Nutrition, Allergology and Pulmonology, Medical University of Bialystok, Bialystok, Poland. Hauptthemen laut MEDLINE: Fibronectins, Fatty Liver, Pediatric Obesity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aim
The purpose of this study was to evaluate irisin, myonectin and high‐sensitivity interleukin‐6 (hs IL‐6) levels in obese children and adolescents and to determine the association of these parameters with metabolic dysfunction–associated steatotic liver disease (MASLD) in children.
Methods
Sixty‐one overweight/obese children with suspected liver disease and seventeen healthy controls were included in the study. MASLD was diagnosed according to the latest consensus. Circulating irisin, myonectin and hs IL‐6 were measured by enzyme‐linked immunosorbent assay (ELISA).
Results
The study group included 38 children meeting MASLD criteria and 23 children without diagnosed hepatic steatosis. The concentrations of the analysed myokines were comparable in the MASLD and non‐MASLD groups. Patients with MASLD were further divided according to the severity of hepatic steatosis. Significantly higher levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase, uric acid and irisin were observed in patients with severe hepatic steatosis compared to mild hepatic steatosis. There were borderline statistically significant positive correlations of irisin with ALT and AST.
Conclusion
We revealed that elevated irisin levels were associated with the degree of hepatic steatosis in MASLD. We also found a borderline significant positive association of irisin with liver enzymes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Gastroenterology, Hepatology, Nutrition, Allergology and Pulmonology, Medical University of Bialystok, Bialystok, Poland.
ORCID-Profile: Katarzyna Zdanowicz
Zitieren
APA
Zdanowicz, K., Kopiczko, N., Flisiak-Jackiewicz, M., Bobrus-Chociej, A., Kowalczuk-Kryston, M., & Lebensztejn, D. M. (2025). Irisin as a marker of hepatic steatosis in children with metabolic dysfunction–associated steatotic liver disease. Acta Paediatrica, 114(3), 578-585. https://doi.org/10.1111/apa.17475
Vancouver
Zdanowicz K, Kopiczko N, Flisiak-Jackiewicz M, Bobrus-Chociej A, Kowalczuk-Kryston M, Lebensztejn DM. Irisin as a marker of hepatic steatosis in children with metabolic dysfunction–associated steatotic liver disease. Acta Paediatrica. 2025;114(3):578-585. doi:10.1111/apa.17475
BibTeX
@article{Zdanowicz2025,
author = {Zdanowicz, Katarzyna and Kopiczko, Natalia and Flisiak-Jackiewicz, Marta and Bobrus-Chociej, Anna and Kowalczuk-Kryston, Monika and Lebensztejn, Dariusz Marek},
title = {Irisin as a marker of hepatic steatosis in children with metabolic dysfunction–associated steatotic liver disease},
journal = {Acta Paediatrica},
year = {2025},
volume = {114},
number = {3},
pages = {578--585},
doi = {10.1111/apa.17475}
}
EUVIMED